查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402924

硬皮症診斷與治療市場 - 全球產業分析、規模、佔有率、成長、趨勢與預測，2023-2031 年

Scleroderma Diagnostics and Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 176 Pages | 商品交期: 2-10個工作天內

價格

硬皮症診斷和治療市場 - 報告範圍

TMR 關於全球硬皮症診斷和治療市場的報告研究了過去以及當前的成長趨勢和機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了全球硬皮症診斷的收入2017-2031 年期間的治療市場，以2023 年為基準年，2031 年為預測年。該報告也提供了2023年至2031年全球硬皮症診斷和治療市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解硬皮症診斷和治療市場。

市場概況
2023年市場價值 22億美元
2031 年市場價值 46 億美元
CAGR 8.7%

該報告深入研究了全球硬皮症診斷和治療市場的競爭格局。全球硬皮症診斷和治療市場的主要參與者已經確定，並且每位參與者都已根據各種屬性進行了分析。公司概況、財務狀況、最新發展和 SWOT 是本報告中介紹的全球硬皮症診斷和治療市場參與者的屬性。

目錄

第 1 章：執行摘要

第 2 章：市場概述

  • 市場區隔
  • 市場走向
  • 市場動態
  • 波特五力分析
  • 監管分析
  • 價值鏈分析
  • 產品規格分析
  • 製造流程概覽
  • 成本結構分析

第 3 章：COVID-19 影響分析

第 4 章：價格趨勢分析

第 5 章：全球市場分析與預測：按藥物類別，2023-2031

  • 簡介和定義
  • 全球市場價值預測：依藥品類別，2023-2031
    • 皮質類固醇
    • 免疫抑制劑
    • 內皮素受體激動劑
    • 鈣通道阻斷劑
    • PD5抑制劑
    • 螯合劑
    • 前列環素類似物
    • H2 阻斷劑
    • 質子幫浦抑制劑
    • ACE抑制劑
  • 全球市場吸引力：按藥品類別

第 6 章：全球市場分析與預測：依指標分類，2023-2031

  • 簡介和定義
  • 全球市場價值預測：依指標分類，2023-2031
    • 系統性
    • 在地化
  • 全球市場吸引力：依指標分類

第 7 章：全球市場分析與預測：按診斷測試類型，2023-2031

  • 簡介和定義
  • 全球市場價值預測：依診斷測試類型，2023-2031
    • 皮膚切片
    • 影像技術
    • 驗血
    • 心電圖和超音波心動圖
    • 肺功能測試
  • 全球市場吸引力：按診斷測試類型

第 8 章：全球市場分析與預測：按地區分類，2023-2031

  • 主要發現
  • 全球市場價值預測：按地區，2023-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 中東和非洲
    • 拉丁美洲
  • 全球市場吸引力：按地區分類

第 9 章：2023-2031 年北美市場分析與預測

第 10 章：2023-2031 年歐洲市場分析與預測

第 11 章：2023-2031 年亞太市場分析與預測

第 12 章：2023-2031 年拉丁美洲市場分析與預測

第 13 章：2023-2031 年中東和非洲市場分析與預測

第 14 章：競爭格局

  • 2022 年全球公司市佔率分析
  • 公司簡介（詳細資訊 - 概述、財務狀況、近期發展和策略）
    • Johnson & Johnson Services, Inc.
    • Boehringer Ingelheim
    • Bayer AG
    • Cytori Therapeutics, Inc.
    • Corbus Pharmaceuticals Holdings Inc.
    • Cumberland Pharmaceuticals, Inc.
    • Gilead Sciences, Inc.
    • Sanofi SA
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Merck & Co., Inc.

第 15 章：初步研究：主要見解

第 16 章：附錄

Product Code: TMRGL2498

Scleroderma Diagnostics and Therapeutics Market - Scope of Report

TMR's report on the global scleroderma diagnostics and therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global scleroderma diagnostics and therapeutics market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global scleroderma diagnostics and therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the scleroderma diagnostics and therapeutics market.

Market Snapshot
Market Value in 2023US$ 2.2 Bn
Market Value in 2031US$ 4.6 Bn
CAGR8.7%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global scleroderma diagnostics and therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global scleroderma diagnostics and therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global scleroderma diagnostics and therapeutics market.

The report delves into the competitive landscape of the global scleroderma diagnostics and therapeutics market. Key players operating in the global scleroderma diagnostics and therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global scleroderma diagnostics and therapeutics market profiled in this report.

Key Questions Answered in Global scleroderma diagnostics and therapeutics Market Report:

  • What is the sales/revenue generated by scleroderma diagnostics and therapeutics across all regions during the forecast period?
  • What are the opportunities in the global scleroderma diagnostics and therapeutics market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Scleroderma Diagnostics and Therapeutics Market - Research Objectives and Research Approach

The comprehensive report on the global scleroderma diagnostics and therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global scleroderma diagnostics and therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global scleroderma diagnostics and therapeutics market.

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Key Facts and Figures
  • 1.4. Trends Impacting Market
  • 1.5. TMR's Growth Opportunity Wheel

2. Market Overview

  • 2.1. Market Segmentation
  • 2.2. Market Trends
  • 2.3. Market Dynamics
    • 2.3.1. Drivers
    • 2.3.2. Restraints
    • 2.3.3. Opportunities
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Regulatory Analysis
  • 2.6. Value Chain Analysis
    • 2.6.1. List of Raw Material Suppliers
    • 2.6.2. List of Key Manufacturers
    • 2.6.3. List of Suppliers/ Distributors
    • 2.6.4. List of Potential Customers
  • 2.7. Product Specification Analysis
  • 2.8. Overview of Manufacturing Process
  • 2.9. Cost Structure Analysis

3. COVID-19 Impact Analysis

4. Price Trend Analysis

5. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Drug Class, 2023-2031

  • 5.1. Introduction and Definitions
  • 5.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 5.2.1. Corticosteroids
    • 5.2.2. Immunosuppressive Agents
    • 5.2.3. Endothelin Receptor Agonists
    • 5.2.4. Calcium Channel Blockers
    • 5.2.5. PD5-Inhibitors
    • 5.2.6. Chelating Agents
    • 5.2.7. Prostacyclin Analogues
    • 5.2.8. H2 Blockers
    • 5.2.9. Proton Pump Inhibitors
    • 5.2.10. ACE Inhibitors
  • 5.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Drug Class

6. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Indication, 2023-2031

  • 6.1. Introduction and Definitions
  • 6.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 6.2.1. Systemic
    • 6.2.2. Localized
  • 6.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Indication

7. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Diagnostic Test Type, 2023-2031

  • 7.1. Introduction and Definitions
  • 7.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 7.2.1. Skin Biopsy
    • 7.2.2. Imaging Techniques
    • 7.2.3. Blood Test
    • 7.2.4. Electrocardiogram and Echocardiogram
    • 7.2.5. Pulmonary Function Tests
  • 7.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Diagnostic Test Type

8. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, by Region, 2023-2031

  • 8.1. Key Findings
  • 8.2. Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Region, 2023-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Middle East & Africa
    • 8.2.5. Latin America
  • 8.3. Global Scleroderma Diagnostics and Therapeutics Market Attractiveness, by Region

9. North America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 9.1. Key Findings
  • 9.2. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 9.3. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 9.4. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 9.5. North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country, 2023-2031
    • 9.5.1. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 9.5.2. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 9.5.3. U.S. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 9.5.4. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 9.5.5. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 9.5.6. Canada Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 9.6. North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

10. Europe Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 10.1. Key Findings
  • 10.2. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 10.3. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 10.4. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.5. Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
    • 10.5.1. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.2. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.3. Germany Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.4. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.5. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.6. France Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.7. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.8. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.9. U.K. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.10. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.11. Italy. Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.12. Italy Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.13. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.14. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.15. Russia & CIS Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 10.5.16. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 10.5.17. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 10.5.18. Rest of Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 10.6. Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

11. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 11.1. Key Findings
  • 11.2. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class
  • 11.3. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 11.4. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 11.5. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
    • 11.5.1. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.2. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.3. China Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 11.5.4. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.5. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.6. Japan Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 11.5.7. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.8. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.9. India Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 11.5.10. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.11. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.12. ASEAN Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 11.5.13. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 11.5.14. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 11.5.15. Rest of Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 11.6. Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

12. Latin America Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 12.1. Key Findings
  • 12.2. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 12.3. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 12.4. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 12.5. Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
    • 12.5.1. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 12.5.2. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 12.5.3. Brazil Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 12.5.4. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 12.5.5. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 12.5.6. Mexico Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 12.5.7. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 12.5.8. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 12.5.9. Rest of Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 12.6. Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

13. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Analysis and Forecast, 2023-2031

  • 13.1. Key Findings
  • 13.2. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
  • 13.3. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
  • 13.4. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 13.5. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Country and Sub-region, 2023-2031
    • 13.5.1. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 13.5.2. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 13.5.3. GCC Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 13.5.4. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 13.5.5. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 13.5.6. South Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
    • 13.5.7. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Drug Class, 2023-2031
    • 13.5.8. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Indication, 2023-2031
    • 13.5.9. Rest of Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • 13.6. Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis

14. Competition Landscape

  • 14.1. Global Scleroderma Diagnostics and Therapeutics Company Market Share Analysis, 2022
  • 14.2. Company Profiles (Details - Overview, Financials, Recent Developments, and Strategy)
    • 14.2.1. Johnson & Johnson Services, Inc.
      • 14.2.1.1. Company Description
      • 14.2.1.2. Business Overview
      • 14.2.1.3. Financial Overview
      • 14.2.1.4. Strategic Overview
    • 14.2.2. Boehringer Ingelheim
      • 14.2.2.1. Company Description
      • 14.2.2.2. Business Overview
      • 14.2.2.3. Financial Overview
      • 14.2.2.4. Strategic Overview
    • 14.2.3. Bayer AG
      • 14.2.3.1. Company Description
      • 14.2.3.2. Business Overview
      • 14.2.3.3. Financial Overview
      • 14.2.3.4. Strategic Overview
    • 14.2.4. Cytori Therapeutics, Inc.
      • 14.2.4.1. Company Description
      • 14.2.4.2. Business Overview
      • 14.2.4.3. Financial Overview
      • 14.2.4.4. Strategic Overview
    • 14.2.5. Corbus Pharmaceuticals Holdings Inc.
      • 14.2.5.1. Company Description
      • 14.2.5.2. Business Overview
      • 14.2.5.3. Financial Overview
      • 14.2.5.4. Strategic Overview
    • 14.2.6. Cumberland Pharmaceuticals, Inc.
      • 14.2.6.1. Company Description
      • 14.2.6.2. Business Overview
      • 14.2.6.3. Financial Overview
      • 14.2.6.4. Strategic Overview
    • 14.2.7. Gilead Sciences, Inc.
      • 14.2.7.1. Company Description
      • 14.2.7.2. Business Overview
      • 14.2.7.3. Financial Overview
      • 14.2.7.4. Strategic Overview
    • 14.2.8. Sanofi S.A.
      • 14.2.8.1. Company Description
      • 14.2.8.2. Business Overview
      • 14.2.8.3. Financial Overview
      • 14.2.8.4. Strategic Overview
    • 14.2.9. Pfizer Inc.
      • 14.2.9.1. Company Description
      • 14.2.9.2. Business Overview
      • 14.2.9.3. Financial Overview
      • 14.2.9.4. Strategic Overview
    • 14.2.10. F. Hoffmann-La Roche AG
      • 14.2.10.1. Company Description
      • 14.2.10.2. Business Overview
      • 14.2.10.3. Financial Overview
      • 14.2.10.4. Strategic Overview
    • 14.2.11. Merck & Co., Inc.
      • 14.2.11.1. Company Description
      • 14.2.11.2. Business Overview
      • 14.2.11.3. Financial Overview
      • 14.2.11.4. Strategic Overview

15. Primary Research: Key Insights

16. Appendix

List of Tables

  • Table 01: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 02: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 03: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 04: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Region, 2023-2031
  • Table 05: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country, 2023-2031
  • Table 06: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 07: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 08: North America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 09: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 11: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 12: Europe Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 13: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 14: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 15: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 16: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 17: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 18: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 19: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 20: Latin America Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031
  • Table 21: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Country/Sub-region, 2023-2031
  • Table 22: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Drug Class, 2023-2031
  • Table 23: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Indication, 2023-2031
  • Table 24: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast, by Diagnostic Test Type, 2023-2031

List of Figures

  • Figure 01: Global Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) and Distribution (%), by Region, 2023 and 2031
  • Figure 02: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Drug Class, 2022
  • Figure 03: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Drug Class, 2022
  • Figure 04: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Indication, 2022
  • Figure 05: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Indication, 2022
  • Figure 06: Global Scleroderma Diagnostics and Therapeutics Market Revenue (US$ Bn), by Diagnostic Test Type, 2022
  • Figure 07: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Diagnostic Test Type, 2022
  • Figure 08: Global Scleroderma Diagnostics and Therapeutics Market Value Share, by Region, 2022
  • Figure 09: Global Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast, 2023-2031
  • Figure 10: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 11: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 12: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 13: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 14: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 15: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 16: Global Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Region, 2023 and 2031
  • Figure 17: Global Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Region, 2022-2031
  • Figure 18: North America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 19: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 20: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country, 2023 and 2031
  • Figure 21: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 22: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 23: North America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 24: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 25: North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 26:North America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 27: Europe Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 28: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 30: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 31: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 32: Europe Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 33: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 34: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 35: Europe Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 36: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 37: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 38: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 39: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 40: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 41: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 42: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 43: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 44: Asia Pacific Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 45: Latin America Scleroderma Diagnostics and Therapeutics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 46: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 47: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 48: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 49: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 50: Latin America Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 51: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 52: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 53: Latin America Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031
  • Figure 54: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (US$ Bn) Forecast and Y-o-Y Growth (%), 2023-2031
  • Figure 55: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 56: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Country/Sub-region, 2023 and 2031
  • Figure 57: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Drug Class, 2023 and 2031
  • Figure 58: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Indication, 2023 and 2031
  • Figure 59: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Value Share Analysis, by Diagnostic Test Type, 2023 and 2031
  • Figure 60: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Drug Class, 2022-2031
  • Figure 61: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Indication, 2022-2031
  • Figure 62: Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Attractiveness Analysis, by Diagnostic Test Type, 2022-2031